Baidu
map

Crit Care Med:重症监护:药师主导干预对患者结局和成本的影响

2018-03-12 吴星 环球医学资讯

2018年2月,发表在《Crit Care Med》的一项由法国和澳大利亚科学家进行的研究,考察了重症监护药师实施的多种质量提升“捆绑”措施对患者结局和成本的影响。

2018年2月,发表在《Crit Care Med》的一项由法国和澳大利亚科学家进行的研究,考察了重症监护药师实施的多种质量提升“捆绑”措施对患者结局和成本的影响。

背景:手术和药物ICU患者的死亡风险很高,且医疗保健系统的成本巨大。本研究的目的是描述药师主导的干预对药物疗法的影响,以及临床策略对ICU患者结局和医院成本的影响。

设计:在法国2个ICUs(分别有16张床和10张床)的干预前后研究。

受试者:ICU患者。

干预:从2013年1月1日至2015年6月30日,将药师观察期与干预期进行比较,期间重症监护药师向临床医师提供关于镇静药物和剂量、机械通气模式和相关装置、抗菌药降阶梯,以及及时移除中心静脉和尿管的推荐。对根据入院时疾病严重程度(APACHE II评分)匹配的患者组之间,入住ICU和住院时长、机械通气时长、死亡率和每位患者的住院成本的差异进行量化。

测量指标和主要结果:在观察期和干预期分别有1519和 1268例患者入院。根据APACHE II评分,对患者进行匹配后,两组均有1164例患者符合评价的标准。干预期与患者住院时长(3.7 d [5.2~2.3 d];p<0.001)、ICU入住时长(1.4 d [2.3~0.5 d];p<0.005)、机械通气时长(1.2 d [2.1~0.3 d];p<0.01),以及每位患者的住院成本(2560欧元[3728~1392欧元];p<0.001)的平均(95% CI[置信区间])降低相关。总成本每月节约10840欧元(10727~10952欧元),主要是由于镇静药物和抗菌药物使用的减少。没有确定可对死亡率产生影响。

结论:重症监护药师主导的干预与ICU入住和住院时长,以及ICU药物成本降低相关。

原始出处:

Leguelinel-Blache G,et al.Impact of Quality Bundle Enforcement by a Critical Care Pharmacist on Patient Outcome and Costs.Crit Care Med. 2018 Feb;46(2):199-207.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1480012, encodeId=c63e148001260, content=<a href='/topic/show?id=f9e0530e169' target=_blank style='color:#2F92EE;'>#患者结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53071, encryptionId=f9e0530e169, topicName=患者结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=faa67597457, createdName=ms5906905816781247, createdTime=Wed Mar 14 12:35:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551131, encodeId=ba0e1551131d3, content=<a href='/topic/show?id=e2c1e230796' target=_blank style='color:#2F92EE;'>#监护#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72307, encryptionId=e2c1e230796, topicName=监护)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477814173963, createdName=bioon6, createdTime=Wed Mar 14 12:35:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608634, encodeId=fc82160863496, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Mar 14 12:35:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=295597, encodeId=a40e29559eac, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Mon Mar 12 21:46:02 CST 2018, time=2018-03-12, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1480012, encodeId=c63e148001260, content=<a href='/topic/show?id=f9e0530e169' target=_blank style='color:#2F92EE;'>#患者结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53071, encryptionId=f9e0530e169, topicName=患者结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=faa67597457, createdName=ms5906905816781247, createdTime=Wed Mar 14 12:35:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551131, encodeId=ba0e1551131d3, content=<a href='/topic/show?id=e2c1e230796' target=_blank style='color:#2F92EE;'>#监护#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72307, encryptionId=e2c1e230796, topicName=监护)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477814173963, createdName=bioon6, createdTime=Wed Mar 14 12:35:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608634, encodeId=fc82160863496, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Mar 14 12:35:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=295597, encodeId=a40e29559eac, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Mon Mar 12 21:46:02 CST 2018, time=2018-03-12, status=1, ipAttribution=)]
    2018-03-14 bioon6
  3. [GetPortalCommentsPageByObjectIdResponse(id=1480012, encodeId=c63e148001260, content=<a href='/topic/show?id=f9e0530e169' target=_blank style='color:#2F92EE;'>#患者结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53071, encryptionId=f9e0530e169, topicName=患者结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=faa67597457, createdName=ms5906905816781247, createdTime=Wed Mar 14 12:35:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551131, encodeId=ba0e1551131d3, content=<a href='/topic/show?id=e2c1e230796' target=_blank style='color:#2F92EE;'>#监护#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72307, encryptionId=e2c1e230796, topicName=监护)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477814173963, createdName=bioon6, createdTime=Wed Mar 14 12:35:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608634, encodeId=fc82160863496, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Mar 14 12:35:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=295597, encodeId=a40e29559eac, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Mon Mar 12 21:46:02 CST 2018, time=2018-03-12, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1480012, encodeId=c63e148001260, content=<a href='/topic/show?id=f9e0530e169' target=_blank style='color:#2F92EE;'>#患者结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53071, encryptionId=f9e0530e169, topicName=患者结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=faa67597457, createdName=ms5906905816781247, createdTime=Wed Mar 14 12:35:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551131, encodeId=ba0e1551131d3, content=<a href='/topic/show?id=e2c1e230796' target=_blank style='color:#2F92EE;'>#监护#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72307, encryptionId=e2c1e230796, topicName=监护)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477814173963, createdName=bioon6, createdTime=Wed Mar 14 12:35:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608634, encodeId=fc82160863496, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Mar 14 12:35:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=295597, encodeId=a40e29559eac, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Mon Mar 12 21:46:02 CST 2018, time=2018-03-12, status=1, ipAttribution=)]
    2018-03-12 天地飞扬

    了解一下.谢谢分享!

    0

相关资讯

右美托咪定预防谵妄

根据美国呼吸与重症医学杂志在线发表的一项最新研究显示,夜间给予的低剂量镇静药物右美托咪定可以预防ICU患者的谵妄。

Ann Intensive Care:他汀类药物治疗对ICU脓毒症患者的宿主反应有影响吗?

2018年,发表在《Ann Intensive Care》上的一项前瞻性观察研究,考察了他汀类药物治疗对重症脓毒症患者宿主反应的影响情况。

Crit Care Med:急诊科和ICU入住率对重症患者入院决定和结局的影响!

由此可见,急诊科就诊的重症患者ICU入院决定受ICU病床的影响,尽管更高的急诊室容量和其他ICU入住率没有发挥作用。长时间的急诊室停留时间与患者恶化的结局相关,提示需要改善就诊的患者吞吐量,并对等待入住ICU的患者进行有针对性的治疗和护理。

[重复]Crit Care:药物预防应激性溃疡能否让接受肠内营养的ICU患者获益?

2018年发表在《Crit Care》上的一项系统评价与meta分析,考察了药物预防应激性溃疡(SUP)对接受肠内营养的重症患者的应激性胃肠道(GI)出血和其他临床结局的获益情况。

JAMA:氟哌啶醇不能预防危重患者谵妄

研究认为氟哌啶醇不能降低危重患者谵妄风险

Crit Care Med:ICU的危险信号!

无菌性和传染性危重疾病通常会导致血管痉挛性休克和强烈的全身炎症反应。先天免疫系统是对传染性和创伤性打击反应的中心。损伤相关的分子模式是从应激或濒死细胞释放的一些小分子。损伤相关的分子模式激活模式识别受体并协调先天免疫反应的前沿。近期,一项发表在杂志Crit Care Med上的综述介绍了损伤相关分子模式的概念以及它们如何激活全身炎症反应,特别是在创伤、神经系统损伤和感染中。此外,还探讨了在极端情况

Baidu
map
Baidu
map
Baidu
map